Could a 5-Day drug course make surgery safer for liver patients with low platelets?

NCT ID NCT06642740

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This study tests whether a 5-day course of avatricopal can safely raise platelet counts in people with chronic liver disease who have low platelets and need surgery. The goal is to see if more patients reach a platelet count of at least 50×10⁹/L on the day of their procedure, which could lower bleeding risks. Researchers will also monitor for side effects like blood clots or bleeding events.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a drug called avatricopal
What this could lead to
If it works, avatricopal could offer a way to safely increase platelet counts before surgery in people with chronic liver disease, reducing the need for platelet transfusions.
What could go wrong
This is a relatively small, early-stage study, so results may not apply broadly. The drug could cause side effects like thrombotic events, and its long-term safety is not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

108 people

The number who actually took part.

Started

Jun 2024

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with chronic liver disease complicated with thrombocytopenia undergoing elective invasive and minimally invasive surgery were admitted to the experimental group for clinical observation.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Voluntarily join the study and sign the informed consent; * Age ≥18 years old, male or female; * Baseline platelet count \< 50×10\^9/L; * Patients with chronic liver disease undergoing elective invasive and minimally invasive surgery; * No fertility requirements. Exclusion Criteria: * History of arterial or venous thrombosis within 6 months prior to baseline; * Plan to receive platelet transfusion or platelet-containing blood products within 7 days prior to baseline visit; * Anticoagulant or antiplatelet therapy cannot be suspended before surgery according to the standard (low-dose aspirin is allowed to continue); * currently receiving treatment with recombinant human thrombopoietin or thrombopoietin receptor agonists (such as rhTPO, Etopopal, or romipristine); * The subjects had severe arteriosclerosis, cerebral thrombosis tendency, coronary artery stenosis \> 70%; * Patients with a history of arterial or venous thrombosis within 6 months before enrollment; * Patients with known portal vein blood flow velocity \< 10 cm/s or previous portal vein thrombosis within 6 months before enrollment; * Prior to enrollment, any known primary blood history (e.g., immune thrombocytopenia, myelodysplastic syndrome, aplastic anemia); * A known history of hereditary prethrombotic syndrome prior to admission (e.g., VLeiden mutation, prothrombin G20210A mutation, or hereditary antithrombin III (ATIII) deficiency); * A history of major cardiovascular disease within the 6 months prior to enrollment (e.g., aggravated congestive heart failure, arrhythmias known to increase the risk of thromboembolic events \[such as atrial fibrillation\], coronary or peripheral arterial stenting or angioplasty, and coronary or peripheral arterial bypass grafting); * the subject is allergic to avatripopal or any of its excipients; * Exclude vulnerable people with mental disorders and other disabilities * The investigator believes that accompanying medical history may affect the safe completion of the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic liver disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Beijing Ditan Hospital,Capital Medical University

    Beijing, Beijing Municipality, 100015, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.